VTAK: New Estonian life science company formed
CeMines™ Inc., a life sciences company specializing in molecular research and development of minimally invasive clinical diagnostics and bioinformatics-based applications for targeted cancer
therapeutics, today announced that Tallinn, Estonia-based CeMines Estonia OÜ, a wholly owned subsidiary of CeMines International Inc., has co-founded VTAK, a privately held company focused on research and commercialization of diagnostic and therapeutic products for cancer.
VTAK is a company founded on the principles of strategic cooperation between private industry, academia and government. In addition to CeMines Estonia OÜ, the co-founders of VTAK include: Tallinn Technical University, Helsinki Yliopiston Säätio, Regional Hospital of North Estonia, ProSyntest AS, Kevelt AS, CeleCure AS, Trial Form Support AB, and InBio OÜ.
VTAK was formed under the Competence Center Programme, in conjunction with ‘Partnership Estonia’ and the Estonian Government, Chamber of Commerce. Competence Centers are R&D institutions established and operated, together, by private enterprise and academic institutions. The mission of VTAK is to ensure a strong focus on applied scientific research, product development and product commercialization.
To read the full press release, click here.
News Source: CeMines Inc. Press Release, 10th January 2005
29 August 2023
Life Science Baltics 2023 | 20-21 September 2023
29 August 2023
NLSDays and NLSDays Nordic Stars 2023